BJOG: An International Journal of Obstetrics &Gynaecology, Volume 132, Issue 4, Page 518-528, March 2025.ABSTRACT Objective We aim to clarify potential risk factors of complications after uterine artery embolisation (UAE). Setting Complications after uterine artery embolisation (UAE) for symptomatic fibroids are rare, but failure of treatment occurs for approximately 13%–24% of patients at 10 years.
Adeline de Wit +3 more
wiley +1 more source
Advanced Science, Volume 12, Issue 8, February 24, 2025.Circular RNA hsa_circ_0005185 functions as a molecular scaffold, facilitating the interaction between OTUB1 and RAB8A, leading to the deubiquitination of RAB8A. This process promotes primary cilia formation and enhances GLI3R production in the Hedgehog signaling pathway, ultimately inhibiting androgen receptor activity and suppressing the progression ...
Aoyu Fan +7 more
wiley +1 more source
Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy
The Prostate, Volume 85, Issue 3, Page 308-314, February 2025.ABSTRACT Background The influence of testosterone on the prostate's immune microenvironment remains unclear. This study aims to elucidate the dynamics of immune cells in the prostate following androgen deprivation therapy (ADT). Methods We retrospectively compared prostate needle biopsy and radical prostatectomy specimens from 33 patients who underwent
Yoshinori Yanai +9 more
wiley +1 more source
Cancer, Volume 131, Issue 1, 1 January 2025.ABSTRACT Background Androgen‐deprivation therapy (ADT) remains a cornerstone in treatment for patients with advanced prostate cancer. ADT is associated with several adverse effects, including osteoporosis, metabolic syndrome, and cardiovascular events, leading to guidelines recommending routine testing to monitor for these toxicities.
Ahmad Mousa +18 more
wiley +1 more source
Targeted chemotherapy for triple-negative breast cancers via LHRH receptor
Oncology Reports, 2011 Triple-negative breast cancer does not express estrogen and progesterone receptors and there is no overexpression/amplification of the HER2-neu gene. Therefore, this subtype of breast cancer lacks the benefits of specific therapies which target these receptors.
Foest, Crispin +5 more
openaire +5 more sources
Basal and stimulated LHRH receptor sites in the pituitary of aging female mice
Gynecological Endocrinology, 1989 We studied the regulation of pituitary luteinizing hormone-releasing hormone (LHRH) receptors in female mice aged 4-8 months (young), 10-14 months (middle-aged) and 15-18 months (old). In intact animals the mean +/- SE pituitary content of LHRH receptor sites ranged from 34.4 +/- 6.3 fmoles to 41.5 +/- 5.0 fmoles and remained constant throughout aging.
Serge Belisle +2 more
openaire +3 more sources
Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer. [PDF]
PLoS One, 2023 Ndinguri M +8 more
europepmc +1 more source
Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives. [PDF]
Cancer Genomics Proteomics, 2023 Costagliola A +4 more
europepmc +1 more source
The Effects of Surgical Androgen Deprivation Therapy for Advanced Prostate Cancer on Peripapillary Retinal Nerve Fiber Layer Thickness. [PDF]
Eurasian J MedUzun F, Fındık H, Kaim M.
europepmc +1 more source
Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents. [PDF]
Cancer Biol MedZhao J, Chen J, Sun G, Shen P, Zeng H.
europepmc +1 more source